Evidence map›Paper›PMID 32965580›Full record

ArticleClinical and experimental medicine2021

DCLK1, a promising colorectal cancer stem cell marker, regulates tumor progression and invasion through miR-137 and miR-15a dependent manner.

Sepideh Razi, Asieh Sadeghi, Zeynab Asadi-Lari, Kevin J Tam, Elham Kalantari, Zahra Madjd

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Diagnostic value of human fecal SDC2 gene in colorectal cancer.American journal of translational research · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Pleiotropic effects of DCLK1 in cancer and cancer stem cells.Frontiers in molecular biosciences · 2022
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sepideh RaziOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Asieh SadeghiDepartment of Pathology, Iran University of Medical Sciences, Tehran, Iran.
Zeynab Asadi-LariDepartment of Biology, University of Toronto, Toronto, Canada.
Kevin J TamDepartment of Urologic Sciences, Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
Elham KalantariOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.
Zahra MadjdOncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. Zahra.madjd@yahoo.com.ORCID http://orcid.org/0000-0001-7329-2583
Iran University of Medical Sciences · IRUniversity of British Columbia · CAUniversity of Toronto · CA

Funding

National Institute for Medical Research Development (IR) 943696
6 · The paper itself

Abstract

Cancer stem cells (CSCs) are thought to be a major player in tumor initiation, progression, and metastasis. Targeting CSCs for elimination presents a promising therapeutic strategy; however, this approach will require a stronger understanding of CSC biology and identification of CSC-specific markers. The present study was conducted to examine the correlation between DCLK1 and miR-137 and miR-15a levels in colorectal cancer. A total of 222 samples, including 181 colorectal cancer specimens, 24 adenomatosis, and 17 non-adenomatosis colonic polyps, were stained for DCLK1 expression using immunohistochemistry. Also, expression of miR-137 and miR-15a was assessed in colorectal cancer with high and low DCLK1 expression levels. Most colorectal cancer specimens (76%) showed strong expression of DCLK1, whereas only 21% of adenomatous and none of non-adenomatous colonic polyps showed strong DCLK1 expression. A significant difference in DCLK1 expression was found between colorectal cancer, adenomatous, and non-adenomatous colonic polyps (P < 0.001). Higher expression of DCLK1 was more frequently detected in colorectal cases with larger tumor size (P = 0.03), poor differentiation (P = 0.03), and lymph node involvement (P = 0.04). Comparison of miR-137 and miR-15a in colorectal cancer cases revealed a significant inverse correlation with DCLK1 expression (P = 0.03 and P = 0.04, respectively). DCLK1 may act as a candidate marker for colorectal cancer stem cells. The critical role of DCLK1 in colorectal cancer suggests that it may represent an early diagnostic marker and therapeutic target; however, further investigation is warranted.

Indexed as

Biomarkers, TumorColorectal NeoplasmsDisease ProgressionDoublecortin-Like KinasesFemaleFollow-Up StudiesHumansIntracellular Signaling Peptides and ProteinsMaleMicroRNAsMiddle AgedNeoplasm InvasivenessNeoplastic Stem CellsPrognosisProtein Serine-Threonine KinasesBiomarkers, TumorDCLK1 protein, humanDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN137 microRNA, humanMIRN15 microRNA, humanProtein Serine-Threonine KinasesCancer stem cellsColorectal cancerDCLK1MiR-137miR-15a

Identifiers

PMID32965580
OpenAlexW3088619282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.